Fosaprepitant

Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States, and in the European Union in January 2008.
Wikipedia contributors, "Fosaprepitant", Wikipedia, revision 1384229259, retrieved 20 November 2026, source, CC BY-SA 4.0.